Apollo Therapeutics has secured an exclusive license from Sunshine Lake Pharma for a clinical-stage dual receptor agonist targeting FGF21 and GLP-1.

Imetelstat is a first-in-class telomerase inhibitor developed by Geron Corporation, targeting the enzyme telomerase.

KOSELUGO® (Selumetinib) Shows Significant Improvement in Response Rate Compared to Placebo in Adults with Symptomatic Neurofibromatosis Type 1.

PF-07328948 is a small molecule drug developed by Pfizer Inc. The drug targets BCKDK and falls within the therapeutic area of cardiovascular diseases.

Autolus Therapeutics has received FDA approval for AUCATZYL® (obecabtagene autoleucel-obe-cel) for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

ADO-Trastuzumab Emtansine, also known as Kadcyla, is an antibody-drug conjugate (ADC) developed by Genentech, a member of the Roche Group.

Marengo shares encouraging initial human safety, tolerability, and clinical activity results for its lead candidate, Invikafusp Alfa (STAR0602).

The application of AI technology in new drug development spans several critical stages, from compound synthesis to drug repurposing.

STORM Therapeutics reveals that it shared encouraging findings from its Phase 1 clinical trial of STC-15, an inhibitor targeting METTL3 RNA methyltransferase.

Fentanyl Citrate is a small molecule drug that targets the μ opioid receptor and is used to treat a range of therapeutic areas including nervous system diseases.

NGGT recently shared promising new data regarding NGGT002, their gene therapy candidate currently in clinical trials for addressing Phenylketonuria (PKU).

Fomivirsen, developed by Isis Pharmaceuticals, is an antisense oligonucleotide that targets the messenger RNA (mRNA) of cytomegalovirus (CMV).